HMOs Told: "Focus On Quality, Not Cost"

12 November 1997

Managed care companies need to redirect their thinking from cost savingsto quality patient care, which will lower overall costs, says the president of the Central Florida Health Care Coalition, Becky Cherney.

Coalition members spend about 7% of the health care budget on prescription drugs, and say that if utilization rates rose costs would fall, depending on HMOs' willingness to select drugs by effectiveness and not cost, she said. Also, HMOs should be "developing physicians, not directing them, and should be selecting doctors on the basis of outcomes, not discount."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight